Stem cell therapy in inflammatory bowel disease: which, when and how?

作者：van Deen Welmoed K^*; Oikonomopoulos Angelos; Hommes Daniel W

来源：Current Opinion in Gastroenterology, 2013, 29(4): 384-390.

DOI：10.1097/MOG.0b013e328361f763

• hematopoietic stem cells
• inflammatory bowel disease
• mesenchymal stem cells

Purpose of reviewStem cell therapy has emerged as a promising therapeutic strategy for inflammatory bowel diseases (IBDs). Currently, stem cell therapy is not part of the standard of care and is usually only performed as a part of clinical trials. In this review, clinical results, proposed underlying mechanisms, and future research directions will be discussed. %26lt;br%26gt;Recent findingsAdministration of mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) has been evaluated for IBD treatment over the past years. MSC therapy is being explored as a treatment option for fistulizing Crohn%26apos;s disease and for luminal Crohn%26apos;s disease. It is shown to be well tolerated, but results on efficacy are inconsistent. HSC transplantation seems to be very effective, but serious adverse events are common. Therefore, future research should focus on improving efficacy of MSC therapy, and on improvement of safety of HSC therapy. %26lt;br%26gt;SummaryBoth MSC and HSC therapy offer clinical potential, but currently are not routinely used for IBD treatment. MSC therapy seems well tolerated but results on efficacy are conflicting. HSC transplantation is shown to be effective but safety concerns remain. Nonetheless, for severe refractory IBD cases, stem cell therapy could well become the next-generation treatment option.

• 出版日期2013-7